Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
Older
Aug 31, 2018
Half Yearly Report and Accounts
Aug 29, 2018
Neuren and Lanstead agree to pause settlements for 120 days
Aug 22, 2018
Appointment of auditor
Aug 22, 2018
Neuren receives initial payment of US$10 million from ACADIA
Aug 16, 2018
Change of Director's Interest Notice
Aug 15, 2018
Change of Director's Interest Notice
Aug 07, 2018
Investor update
Aug 07, 2018
Neuren and ACADIA announce agreement for North America
Jul 31, 2018
Appendix 4C - quarterly
Jul 09, 2018
Initial Director's Interest Notice
Previous
1
2
3
4
Next
